Status:
COMPLETED
Observational Study in Infants Who Are Prescribed Treatment With Keppra® (Levetiracetam) Oral Solution
Lead Sponsor:
UCB Pharma
Conditions:
Epilepsy
Eligibility:
All Genders
1-11 years
Brief Summary
The purpose of this observational study is to broaden the knowledge of the known safety and efficacy profile of Keppra® (Levetiracetam) oral solution in epileptic infants younger than 12 months when t...
Detailed Description
This non-interventional sentinel sites post-authorization safety study (PASS) aims to collect additional data on use of Keppra® (Levetiracetam) oral solution in clinical practice, and on efficacy and ...
Eligibility Criteria
Inclusion
- diagnosis of epilepsy
- being treated with Keppra® Oral Solution
- aged between 1 month and 11 months inclusive at study baseline
Exclusion
- none
Key Trial Info
Start Date :
January 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2013
Estimated Enrollment :
101 Patients enrolled
Trial Details
Trial ID
NCT01210690
Start Date
January 1 2011
End Date
November 1 2013
Last Update
November 19 2014
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
012
Amiens, France
2
010
Bron, France
3
011
Paris, France
4
027
Berlin, Germany